等待开盘 04-02 09:30:00 美东时间
0.000
0.00%
今日重点评级关注:花旗:维持Candel Therapeutics"买入"评级,目标价从22美元升至26美元;Chardan Capital:维持CervoMed"买入"评级,目标价从15美元升至21美元
03-19 14:31
Cytokinetics granted stock options and RSUs to 5 new employees in February and March 2026, totaling 8,628 shares and 5,719 RSUs, respectively. The RSUs vest over 3 years (40% on year 1, 40% on year 2, 20% on year 3), while the stock options vest over 4 years with monthly installments after the first year. The exercise price was $60.06 per share, matching the closing price on March 13, 2026. These awards align with Nasdaq Listing Rule 5635(c)(4) a...
03-18 20:00
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $74 to $75.
03-17 22:30
Stifel Nicolaus analyst James Condulis reiterated a Buy rating on Cytokinetics ...
03-17 19:25
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson March 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biogen, Eli Lilly and Johnson & Johnson on Tuesday. HIGHLIGHTS * Biogen BIIB.O : HSBC raises target pri
03-17 15:31
Cytokinetics announced four MYQORZO™ (aficamten) presentations at the 2026 ACC meeting, highlighting new analyses supporting its efficacy in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Data shows aficamten improves exercise capacity vs placebo or metoprolol while maintaining safety. Studies also demonstrate its ability to safely interrupt treatment and reinitiate without significant adverse effects, and its effectiveness ...
03-16 12:00
今日重点评级关注:HC Wainwright & Co.:维持BridgeBio Oncology"买入"评级,目标价从27美元升至29美元;韦德布什:维持WAVE Life Sciences"跑赢大市"评级,目标价从33美元升至35美元
03-09 11:47
UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and raises the price target from $61 to $69.
03-07 03:17
Tango Therapeutics reported a cash position of $343 million as of December 31, 2025, supporting operations into 2028. The company expects to initiate a pivotal study for vopimetostat in 2L MTAP-deleted pancreatic cancer in 2026. Vopimetostat combinations with RAS(ON) inhibitors in pancreatic and lung cancer are showing promising safety and efficacy. Initial Phase 1/2 data are anticipated in 2026. The company also entered a clinical supply agreeme...
03-05 12:00